Pharmacovigilance of tilmicosin in mice
Gheith, IbtsamEl-Mahmoudy, AbubakrElmajdub, AbdelrazzagAwidat, Shaban
Background: Tilmicosin is a macrolide antibiotic used mainly for controlling respiratory infections in animals. Tilmicosin therapy, like that with other macrolide members, may be associated with various adverse effects on different organ functions that remain a controversial matter. Therefore, the object of the present study was to investigate the adverse effects of tilmicosin, a relatively new macrolide, on biochemical and haematological parameters as well as histological structure in mice in a trial to evaluate its safety after administration of a small and larger doses subcutaneously.Materials, Methods & Results: Forty male Swiss albino mice were assigned randomly to four groups; the first group was untreated while the other three were treated with escalating doses of tilmicosin (20, 40 & 60 mg/Kg, SC). Tilmicosin caused tender swellings at the site of injection and animals received a dose 60 mg/kg of body weight died shortly postadministration. Animals received smaller doses, 20 & 40 mg/kg of body weight survived and blood, plasma and tissue samples showed marked dose-dependent alterations. Tilmicosin significantly decreased all (but not MCV) erythrocytic parameters and indices including, RBC count, HCT, HGB, MCH and MCHC. Additionally, lymphocytes exhibited significant decrease, while granulocytes exhibited significant increase compared to control. Hepatorenal function markers including, ALP, ALT, AST, urea and creatinine showed significant increases, compared to control, particularly post-administrating 40 mg/kg of body weight dose. Cardiac function marker, CK, showed significant increase after both doses of tilmicosin. Significant decreases in TP, ALB and GLB concentrations compared to control; and, on contrary, significant increases in CHOL, TAG and GLU were also recorded. Parallel dose-dependent degenerative changes were also observed in liver, kidney, heart and spleen tissue samples picked from treated groups.[...](AU)
Texto completo